Alex Tarrabain - 02 Apr 2021 Form 4 Insider Report for CEN BIOTECH INC

Role
Chief Financial Officer, Director
Signature
/s/ /Alex Tarrabain
Issuer symbol
N/A
Transactions as of
02 Apr 2021
Net transactions value
+$48,000
Form type
4
Filing time
03 Jun 2021, 08:34:03 UTC
Previous filing
28 May 2021
Next filing
25 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CENBF Common Stock Other $0 +3,000 +0.17% $0.000000 1,772,942 16 Jan 2021 Direct F3
transaction CENBF Common Stock Other $0 +3,000 +0.17% $0.000000 1,772,942 16 Feb 2021 Direct F3
transaction CENBF Common Stock Other $0 +3,000 +0.17% $0.000000 1,772,942 16 Mar 2021 Direct F3
transaction CENBF Common Stock Award $0 +300,000 +20% $0.000000 1,772,942 02 Apr 2021 Direct F1
transaction CENBF Common Stock Conversion of derivative security $48,000 +30,000 +1.7% $1.60* 1,772,942 10 Apr 2021 Direct F2
transaction CENBF Common Stock Other $0 +3,000 +0.17% $0.000000 1,772,942 16 Apr 2021 Direct F3
transaction CENBF Common Stock Other $0 +3,000 +0.17% $0.000000 1,772,942 16 May 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 300,000 shares of common stock of the issuer were granted by the issuer on April 2, 2021, pursuant to a restricted stock agreement pursuant to the issuer's equity compensation plan and the issuance was approved by the issuer's full board of directors.
F2 30,000 shares of common stock of the issuer were issued to the reporting person on April 10, 2021, pursuant to the conversion of a $48,000 convertible promissory note issued on October 26, 2016.
F3 3,000 shares of common stock of the issuer were issued to the reporting person on January 16, 2021, February 16, 2021, March 16, 2021, April 16, 2021 and May 16, 2021, as consideration for extending the maturity date of a promissory note dated January 14, 2018.